BREAKING NEWS Urgent recall for fruit sold in multiple states that could kill if eaten
Health officials are sounding the alarm over deadly apricots sold in nearly 20 states over fears of them containing worrying levels of undeclared sulfites.
The FDA has asked consumers to stop eating Turkana Food Inc.'s Floria Dried Apricots with an expiration date of November 2026.
Sulfites are used as food additives to preserve freshness and prevent spoilage in various items such as wine, dried fruits and processed foods.
But depending on how much of the additive is present, some people may show sensitivities and can experience reactions like hives, swelling, abdominal pain, diarrhea or in rare cases, life-threatening allergic reactions.
According to FDA regulations, companies are required to declare the amount of sulfites used in each product on every individual packaging.
However, during a routine sampling performed by the New York State Department of Agriculture, the agency found packaging for Turkana Food Inc.'s apricots was missing its product labeling for sulfites.
The affected product has been sold in Florida, Kentucky, Virginia, New York, New Jersey, Tennessee, Massachusetts, Texas, Illinois, Indiana, Michigan, Rhode Island, Pennsylvania, North Carolina, Maryland, Ohio, Alabama, Missouri and California.
No cases of illness have been reported.
The impacted product has a LOT number of 440090478-15-333 that can be found at the bottom of the packaging.
It also has a UPC Label of 2539560010 that can be seen on a sticker at the top of the package that can be used for identification.
The FDA has asked consumers to not eat the recalled dried apricots and return them to their original place of purchase for a refund.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Medical News Today
an hour ago
- Medical News Today
Celiac disease: Is an easier way to diagnose it on the horizon?
Could a blood test diagnose celiac disease without the need to trigger symptoms? Image credit: Alvaro Lavin/Stocksy. Celiac disease has to do with an abnormal immune response of the body to gluten. Experts are interested in the best ways to test for celiac disease. A recent study discovered that a blood test called WBAIL-2 could aid in diagnosing celiac disease and even contribute to biopsy-free diagnosis. Celiac disease occurs when someone's immune system responds abnormally to gluten. Efforts to improve celiac disease diagnosis are ongoing. A study recently published in Gastroenterology evaluated the effectiveness of using a blood test that measures the cytokine interleukin-2 to diagnose celiac disease. The study's results indicated that the test to be highly effective for celiac disease diagnosis, even for people following a gluten-free diet. The test could offer another option to help with celiac disease diagnosis — importantly, one that would not require triggering symptoms to confirm the disease. The authors of the current study note that there is often a delay or lack of diagnosis when it comes to celiac disease. Diagnosis usually involves people having to eat gluten and get biopsies of the small intestine. Celiac disease also has to do with the response of a group of immune cells, CD4+ gluten-specific T-cells. For this study, researchers wanted to determine if the use of a blood test that measures interleukin-2 — a protein produced by some T-cells — release could help to accurately diagnose celiac disease. This research involved a total of 181 adult participants between 18 and 75 years old. Of these participants, 88 had celiac disease, and others were controls. Among controls, 32 participants had a non-celiac gluten sensitivity and were on a gluten-free diet. The rest were healthy controls who did not have gluten sensitivity. All participants provided blood samples, and researchers collected data on medications and medical history. A subset of participants, including healthy controls, participants with non-celiac gluten sensitivity, and treated celiac disease, went on a gluten-free diet for four weeks or more and then consumed gluten for 'a single-dose open-label gluten challenge.' Some participants with treated celiac disease also did an oral gluten challenge that lasted 3 days. If participants underwent the oral gluten challenge, they used diaries to keep track of their symptoms. Researchers utilized a blood test called a WBAIL-2 assay, which measures the release of interleukin-2 in vitro after adding gluten peptides. In general, the test was able to effectively confirm celiac disease, with higher concentrations and fold change of interleukin-2 in participants who had celiac disease. However, the results were less sensitive for participants with a certain, less common genotype. Analysis results also found that the WBAIL-2 assay correlated with age and the number of years participants had been following a gluten-free diet. Next, researchers tested participants' serum levels of interleukin-2 after they did an oral gluten challenge. The levels of interleukin-2 were higher for participants with celiac disease following the oral gluten challenge. Researchers also found these levels 'positively correlated with the WBAIL-2 results.' So, if the levels of interleukin-2 were elevated on one test, they were also elevated on the other. They also tested how the WBAIL-2 results related to the presence of gluten-specific T cells, which were higher among participants with celiac disease. They did find that the presence of these cells, as well as activated versions of these cells, correlated with the WBAIL-2 test. The researchers further found that gluten-specific T cells, activated versions of these cells, and WBAIL-2 increased after participants underwent a gluten challenge. However, one participant had lower gluten-specific CD4+ T cells and a lower WBAIL-2 test on day six. Researchers also looked at treated celiac disease participants and how the tests related to their symptoms after gluten exposure. When it came to gluten-specific T-cells, their frequency was higher in participants who experienced vomiting. The measurement of serum interleukin-2 following the gluten tolerance test was also elevated, as was the WBAIL-2 level. The WBAIL-2 level was also increased greatly for one participant who did not experience vomiting but did report severe tiredness. Further analysis also suggested that activated gluten-specific CD4+ T cells are the cells that lead to gluten-induced production of interleukin-2. The results suggest that the WBAIL-2 assay can help with celiac disease diagnosis, even when people are already following a gluten-free diet. There are some limitations to this study. For one thing, it was performed out of one area, most participants were female, and there were strict inclusion criteria, so it has a limited generalizability. It also had small sample sizes for some subgroups, which means more research may be particularly necessary in these subgroups. Since researchers did not test children or people taking immunosuppressants, more research is needed to see how well this testing method would work in these populations. Researchers also acknowledge an untested 'reproducibility across laboratories.' More research is thus needed before the WBAIL-2 assay can really be used in the clinical setting. Further, the authors did not examine the cost-effectiveness of the WBAIL-2 test and how well this would stack up against current ways of diagnosing celiac disease. Then, the test was not as accurate for some participants with a specific genotype, which means it might not work for everyone. However, the number of participants with this genotype was very small in this study, and it is possible that the level of interleukin-2 response of some participants with this genotype was just not able to be detected by the test. Overall, more research is required regarding this subtype of individuals and the use of this test. Ian Storch, DO, an osteopathic physician specializing in gastroenterology and internal medicine, and an American Osteopathic Association member, who was not involved in this study, spoke to Medical News Today about its findings. 'One limitation of this study is the poor performance in the DQ8 genetic arm, which makes up 10% of celiac patients. This will decrease the sensitivity and specificity for the control group or require HLA typing before the assay is run.' Researchers acknowledge that the serum analysis of interleukin-2 following a gluten challenge does not always line up with the results of the WBAIL-2 assay, which could have to do with the assays' differences. Shilpa Mehra Dang, MD, double board-certified in gastroenterology and internal medicine with Medical Offices of Manhattan and contributor to LabFinder, who was similarly not involved in this research, noted that 'we need to look at bigger samples to really see its clinical usefulness.' In addition to larger studies, research can also focus on more details regarding gluten-specific T cells. Celiac disease is a challenging condition to manage, and accurate diagnosis is important. Researchers suggest that examining WBAIL-2 and serum interleukin-2 after gluten consumption could allow people with celiac disease to not have to get biopsies done to confirm celiac diagnosis. The authors of this study also suggest that the WBAIL-2 assay could also become a first test among people following a gluten-free diet and help with symptom severity prediction. Storch said: 'I do not think that based on the data presented, removal of histology to confirm the diagnosis can be suggested.' Jeffrey D. Davis, DO, CMD, an osteopathic physician specializing in Family Medicine and Preventive Health and an American Osteopathic Association board member, who was not involved in the study, noted the following to MNT : 'I see potential for a commercially available rapid, simple, cost-effective laboratory test for physicians to use to assist in the accurate diagnosis of celiac disease. This study shows that especially in adults already on a gluten-free diet using this lab test versus currently available tests would improve our diagnostic capabilities for Celiac Disease. However, it would most likely be just another tool in our tool box to aid in the diagnosis along with other current diagnostic methods.'
Daily Mail
an hour ago
- Daily Mail
Surprising ingredient in dessert favorites that raises your risk of a heart attack
Cardiologists are warning of an often overlooked ingredient in desserts that can lead to high blood pressure if consumed in excess. Typically a garnish on cookies, bread and butter, soft pretzels, and caramel treats, coarse sea salt contains more sodium than its less expensive grocery store alternative. People enjoy the added crunch and marriage of savory and sweet in desserts, but people are inadvertently eating too much salt. Because coarse salt has larger crystals, it may feel less salty per bite, leading some people to use more than they would with fine salt. Excessive sodium intake is linked to high blood pressure, heart disease, stroke, and kidney problems. The body only needs a small amount of sodium to function properly. Sodium is an essential electrolyte that plays several critical roles in the body, including maintaining fluid balance and blood pressure, supporting nerve function, and enabling muscle contractions. Most Americans consume too much sodium, though – 3,300 mg per day on average, or about 40 percent more than the recommended 2,300mg limit. People tend to believe that coarse sea salt contains less sodium than standard fine salt, yet both contain about 40 percent sodium. Salt lurks everywhere in the Western diet, not just in processed meats, snack foods, but in unsuspecting foods, including breads, canned soups, frozen meals, cheese, sauces, and marinades. An estimated 89 percent of adults and around 94 percent of children consume too much sodium, according to the CDC. Eating too much salt is a major setup for high blood pressure. The World Health Organization also estimates that 1.9 million deaths globally each year can be attributed to eating too much salt. As sodium causes the body to retain fluids, blood volume and pressure on artery walls increase. High blood pressure is a significant risk factor for heart disease, stroke, kidney disease, and other serious health issues. Dr Brent Egan, an internist and vice president of cardiovascular health at the American Medical Association, said: 'It would take us about a little over 1,000 milligrams a day to get from where we are to where the recommendation would be for the upper limit.' 'And if we did that, we'd probably see a significant reduction in blood pressure, heart attack and stroke.' Roughly 116 million Americans have high blood pressure. Approximately 805,000 heart attacks occur each year, as well as 795,000 strokes. 'If someone has high blood pressure, heart disease, that type of thing, 1,500 milligrams is probably a better target, but for the general population that's really interested in limiting the burden of chronic disease, 2,300 milligrams is generally what is recommended,' Dr Egan said. Too much sodium also causes bloating – the uncomfortable feeling that the stomach is swollen and tight. Body parts like hands, feet, and ankles are likely to swell. And feelings of thirst take over due to dehydration. Too much salt before bed can also cause restless sleep. Studies suggest high-salt diets may alter cortisol (stress hormone) levels, which regulate sleep-wake cycles. A recent study by researchers at Vanderbilt University found that reducing daily salt intake by just one teaspoon is as effective as blood pressure medication. They tested high and low-salt diets on hundreds of patients, some of whom had high blood pressure, and found that cutting out a can of Heinz soup each day lowered people's blood pressure by six percent within a week. This reduction was comparable to that of thiazide diuretic hydrochlorothiazide, a popular blood pressure medication. 'Obviously we need some sodium—it's essential for life,' Dr Egan said. But 'here we are with an average intake of 3,400 milligrams. 'Now the body has to make a lot of adjustments, but we can get by with very little sodium,' he said, noting 'there's very little danger in this country that most people won't get enough sodium, even if they're eating those fresh foods and not processed foods. 'They'll still—for the most part—get more than sufficient sodium that the body needs,' said Dr. Egan. 'We live in a state of pretty much constant excess.'
Metro
6 hours ago
- Metro
Urgent recall for vitamin gummies over 'life-threatening health risk'
Vitamin gummies have been recalled across the US because they may contain an undeclared allergen – peanuts. Vita Warehouse Corp is recalling a lot of its Welby brand Vitamin B12 Energy Support gummy product 1000 mcg gummies, Berkely Jensen Vitamin B12 1000 mcg Gummies, and VitaGlobe Vitamin B12 Extra Strength Gummies. 'People with an allergy or severe sensitivity to peanuts run the potential risk of serious or life-threatening allergic reactions if they consume these products,' states an advisory published by the US Food and Drug Administration (FDA) on Friday. The Webly vitamins came with 140 gummies in a clear bottle with a white cap and a green, red and white label. They have an expiration date of October 2026, the UPC code 4099100290868 and the lot number 248046601 printed at the bottom. Berkley Jensen vitamins under the recall came with 250 gummies in a clear bottle with a white cap and red and pink labels. They have an expiration date of October 2026, the UPC code 888670132487 and the lot number 248046601. The VitaGlobe vitamins came with 60 gummies in a clear bottle with a white cap and green, red and white labels. They have the same expiration date as the other two brands, the UPC code 850005214670 and the lot number 248046601. They were sent to ALDI and BJ's stores nationwide. There have not been any allergic reactions or illnesses linked to the vitamins that have been reported. More Trending Anyone who experiences an allergic reaction should see a doctor right away. Customers who are allergic to peanuts should throw them away immediately or return them for a full refund. 'Vita Warehouse Corp is committed to maintaining the highest product safety and quality standards,' states the FDA notice. It comes a week after Aldi recalled its Casa Mamita Churro Bites Filled with Chocolate Hazelnut Cream because they were found to have an undeclared allergen, milk, that could cause 'a serious or life-threatening allergic reaction'. Get in touch with our news team by emailing us at webnews@ For more stories like this, check our news page. MORE: Man 'urinates on $10,000 worth of Spam and sausages forcing them to be tossed' MORE: Everything to know about Donald Trump's military parade on his 79th birthday MORE: Lawmaker forcefully removed from Trump secretary's LA protests conference and handcuffed
